-
بيت
-
منتج
-
الكيمياء المناعية
-
أداة
-
جزيئي
-
الأنسجة
-
علم الخلايا
-
علم الأمراض الرقمية
-
-
Solution
-
يدعم
-
عن
-
اتصال
فئة المنتج
RET Breakapart
Clinic Significance：
1.This occurs in 1-2% of patients with non-small cell lung adenocarcinoma
2.The expression was lower in normal lung tissue, and the gene rearrangement activated the kinase active domain of RET, and the expression was higher in lung cancer samples.
Three targeted drugs, Vandetanib, Sorafenib and Sunitinib, inhibit the activity of multiple receptor tyrosine kinases including RET, and to kill cells carrying RET fusion gene.
محادثة
رسالة
يقتبس
Contrast
RET Normal
RET Breakapart
مزيد من المعلومات
Probe Description: RET
Cat.No.: CF1019
Specification: 10 tests/box, 20 tests/box
المنتج ذي الصلة
